-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Reviewing Arcellx (NASDAQ:ACLX) & Achilles Therapeutics (NASDAQ:ACHL)
Reviewing Arcellx (NASDAQ:ACLX) & Achilles Therapeutics (NASDAQ:ACHL)
Arcellx (NASDAQ:ACLX – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Insider and Institutional Ownership
91.8% of Arcellx shares are held by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Get Arcellx alerts:Analyst Recommendations
This is a breakdown of current recommendations and price targets for Arcellx and Achilles Therapeutics, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
Profitability
This table compares Arcellx and Achilles Therapeutics' net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Achilles Therapeutics | N/A | -26.40% | -23.89% |
Earnings & Valuation
This table compares Arcellx and Achilles Therapeutics' revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.71 |
Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.48 |
Arcellx is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Achilles Therapeutics beats Arcellx on 7 of the 10 factors compared between the two stocks.
About Arcellx
(Get Rating)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
About Achilles Therapeutics
(Get Rating)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
Arcellx (NASDAQ:ACLX – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
納斯達克:ACLX-GET評級)和阿喀琉斯治療公司(納斯達克:ACHL-GET評級)都是小盤醫療公司,但哪隻股票更優越?我們將根據這兩家公司的股息、估值、機構所有權、分析師建議、盈利能力、風險和收益的實力進行比較。
Insider and Institutional Ownership
內部人與機構持股
91.8% of Arcellx shares are held by institutional investors. Comparatively, 69.7% of Achilles Therapeutics shares are held by institutional investors. 5.4% of Achilles Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Arcellx 91.8%的股份由機構投資者持有。相比之下,阿喀琉斯治療公司69.7%的股份由機構投資者持有。阿喀琉斯治療公司5.4%的股份由內部人士持有。強大的機構持股表明,大型基金管理公司、對衝基金和捐贈基金相信,一隻股票的長期表現將好於大盤。
Analyst Recommendations
分析師建議
This is a breakdown of current recommendations and price targets for Arcellx and Achilles Therapeutics, as provided by MarketBeat.
這是MarketBeat提供的Arcell和Achilles治療公司目前的建議和價格目標的細目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Arcellx | 0 | 0 | 8 | 0 | 3.00 |
Achilles Therapeutics | 0 | 1 | 2 | 0 | 2.67 |
銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
阿爾塞克斯 | 0 | 0 | 8 | 0 | 3.00 |
阿喀琉斯治療學 | 0 | 1 | 2 | 0 | 2.67 |
Profitability
盈利能力
This table compares Arcellx and Achilles Therapeutics' net margins, return on equity and return on assets.
此表比較了Arcell和Achilles Treeutics的淨利潤率、股本回報率和資產回報率。
Net Margins | Return on Equity | Return on Assets | |
Arcellx | N/A | -68.99% | -42.26% |
Achilles Therapeutics | N/A | -26.40% | -23.89% |
淨利潤率 | 股本回報率 | 資產回報率 | |
阿爾塞克斯 | 不適用 | -68.99% | -42.26% |
阿喀琉斯治療學 | 不適用 | -26.40% | -23.89% |
Earnings & Valuation
收益與估值
This table compares Arcellx and Achilles Therapeutics' revenue, earnings per share and valuation.
此表比較了Arcell和Achilles Treeutics的收入、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Arcellx | N/A | N/A | -$64.97 million | ($44.41) | -0.71 |
Achilles Therapeutics | N/A | N/A | -$61.10 million | ($1.66) | -0.48 |
總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
阿爾塞克斯 | 不適用 | 不適用 | -6,497萬元 | ($44.41) | -0.71 |
阿喀琉斯治療學 | 不適用 | 不適用 | -6,110萬美元 | ($1.66) | -0.48 |
Arcellx is trading at a lower price-to-earnings ratio than Achilles Therapeutics, indicating that it is currently the more affordable of the two stocks.
Arcellx的市盈率低於阿喀琉斯治療公司,這表明它目前是兩隻股票中更負擔得起的一隻。
Summary
摘要
Achilles Therapeutics beats Arcellx on 7 of the 10 factors compared between the two stocks.
在兩隻股票之間的10個因素中,阿喀琉斯治療公司有7個因素超過了Arcell。
About Arcellx
關於Arcellx
(Get Rating)
(獲取評級)
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Arcell,Inc.是一家臨牀階段的生物技術公司,致力於為癌症和其他不治之症患者開發各種免疫療法。該公司主要的ddCAR候選產品是CART-ddBCMA,這是一種治療復發或難治性(r/r)多發性骨髓瘤(MM)患者的第一階段臨牀試驗。該公司還在開發ACLX-001,這是一種由ARC-T細胞和針對BCMA的雙價SPARX蛋白組成的免疫治療組合,用於治療r/r MM;ACLX-002和ACLX-003用於治療r/r急性髓系白血病(AML)和骨髓增生異常綜合徵(MDS);以及其他AML/MDS候選產品,以及實體腫瘤計劃。該公司前身為Encarta治療公司,並於2016年1月更名為Arcell,Inc.。Arcell,Inc.成立於2014年,總部位於馬裏蘭州蓋瑟斯堡。
About Achilles Therapeutics
阿喀琉斯療法公司簡介
(Get Rating)
(獲取評級)
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.
阿喀琉斯治療公司是一家臨牀階段免疫腫瘤學生物製藥公司,開發用於治療各種實體腫瘤的精密T細胞療法。該公司的主要候選產品包括用於治療晚期非小細胞肺癌的處於I/IIa階段臨牀試驗的ChIron和用於治療轉移性或復發黑色素瘤的處於I/IIa階段臨牀試驗的候選產品Thetis。它還在開發用於治療頭頸部鱗狀細胞癌、腎細胞癌、三陰性乳腺癌和膀胱癌的產品。該公司前身為Achilles TX Limited,2021年2月更名為Achilles Treateutics Plc。該公司成立於2016年,總部設在英國倫敦。
Receive News & Ratings for Arcellx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcellx and related companies with MarketBeat.com's FREE daily email newsletter.
接受Arcell Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收Arcell和相關公司的最新新聞和分析師評級的每日簡明摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧